期刊文献+

人肝癌组织中EpCAM的表达及其意义

下载PDF
导出
摘要 目的探讨EpCAM在肝细胞癌中的表达及其临床意义,为获取肝癌诊断相关的蛋白分子提供实验资料。方法采用组织芯片和免疫组化技术检测EpCAM在肝癌组织、癌旁组织及其癌旁正常组织中的表达。结果 EpCAM在肝癌组织、癌旁组织、癌旁正常组织中的阳性率分别为81.7%(49/60)、61.7%(37/60)、0,三组间差异有统计学意义(P<0.01)。肝癌组织中EpCAM高表达与临床分期、病理分级和民族相关(P<0.05),与患者年龄、肿瘤直径、AFP值、包膜完整度和门脉瘤栓无关(P>0.05)。EpCAM阳性肝癌患者的生存期短于阴性患者,但两组间差异无统计学意义(P>0.05)。结论 EpCAM在肝癌组织中表达上调,其可能参与原发性肝癌发生、发展的恶性进程。
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第9期1047-1049,共3页 Chinese Journal of Clinical and Experimental Pathology
基金 广西科学研究与技术开发计划项目(1355005-3-10) 广西医科大学青年科学基金(GXMUYSF201215)
  • 相关文献

参考文献15

  • 1Ogawa K,Tanaka S,Matsumura S,et al.EpCAMtargeted therapy for human hepatocellular carcinoma[J].Ann Surg Oncol,2014,21(4):1314-22.
  • 2Yamashita T,Wang X W.Cancer stem cells in the development of liver cancer[J].J Clin Invest,2013,123(5):1911-8.
  • 3Nio K,Yamashita T,Okada H,et al.Defeating EpCAM liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma[J].J Hepatol,2015,63(5):1164-72.
  • 4Song K,Wu J,Jiang C.Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review) [J].Oncol Rep,2013,29(1):3-12.
  • 5宁淑芳,许飒,利基林,张力图.CD90和EpCAM在人肝癌细胞系中的表达及EpCAM^+细胞的特性分析[J].中国细胞生物学学报,2015,37(1):47-52. 被引量:1
  • 6Murakata A,Tanaka S,Mogushi K,et al.Gene expression signature of the gross morphology in hepatocellular carcinoma[J].Ann Surg,2011,253(1):94-100.
  • 7Dolle L,Theise N D,Schmelzer E,et al.EpCAM and the biology of hepatic stem/progenitor cells [J].Am J Physiol Gastrointest Liver Physiol,2015,308(4):G233-50.
  • 8Yamashita T,Ji J,Budhu A,et al.EpCAMpositive hepatocellular carcinoma cells are tumorinitiating cells with stem/progenitor cell features[J].Gastroenterology,2009,136(3):1012-24.
  • 9Ji J,Zheng X,Forgues M,et al.Identification of microRNAs specific for epithelial cell adhesion moleculepositive tumor cells in hepatocellular carcinoma[J].Hepatology,2015,62(3):829-40.
  • 10Ogasawara S,Akiba J,Nakayama M,et al.Epithelial cell adhesion moleculepositive human hepatic neoplastic cells:development of combined hepatocellularcholangiocarcinoma in mice[J].J Gastroenterol Hepatol,2015,30(2):413-20.

二级参考文献44

  • 1Ming Lu,Jing Gao, Xi-cheng Wang, Lin Shen.Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class Ⅲ β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin[J].Chinese Journal of Cancer Research,2011,23(4):288-294. 被引量:22
  • 2徐农.药物遗传学在结直肠癌化疗中的应用[J].实用肿瘤杂志,2005,20(6):469-472. 被引量:5
  • 3Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 2014; 64(7): 935-50.
  • 4Zhu Z, Hao X, Yah M, Yao M, Ge C, Gu J, et al. Cancer stem/ progenitor cells are highly enriched in CD 133+CD44~ population in hepatocellular carcinoma. Int J Cancer 2009; 126(9): 2067-78.
  • 5Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea-- a paradigm shift. Cancer Res 2006; 66(4): 1883-90; discussion 1895-6.
  • 6Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: More than a carcinoma marker and adhe-sion molecule. Am J Pathol 2007; 171(2): 386-95.
  • 7Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Bio12009; 11(2): 162-71.
  • 8Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007; 5(6): 553-67.
  • 9Benko G, Spajic B, Kruslin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Onco12013; 31(4): 468-74.
  • 10Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69(14): 5627-9.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部